Ask most biotech computational leads how many times their infrastructure has been rebuilt as a program advanced, and the honest answer is usually “at least once, right when we could least afford it.” It’s such a common pattern that many teams treat it as inevitable. It isn’t.
Why discovery-stage tools break at the stage gate
Discovery-stage infrastructure is often built under exactly the pressure you’d expect: move fast, prove the biology, worry about scale later. That’s a reasonable trade-off — until the program advances toward IND-enabling studies and the infrastructure that was fine for a single discovery push suddenly needs to support regulatory-grade data handling, audit trails and long-term reproducibility it was never designed for.
At that point, teams face an expensive choice: rebuild the infrastructure during exactly the window when the program needs stability the most, or carry technical debt into a regulatory-facing process where debt is the last thing you want.
Where the breaking points usually show up
- Scripts with no containerization, so “it worked on the analyst’s laptop” can’t be reproduced or audited later.
- Data models built around a single study, with no path to link discovery, translational and clinical data.
- Security and access control added as a pre-filing checklist item instead of an architecture decision.
Nuclyra is the only partner we didn’t have to re-explain our program to when we moved from discovery into IND-enabling studies.
Designing for the next stage, not just this one
The fix isn’t over-engineering a discovery-stage tool for a regulatory bar it doesn’t need yet. It’s making a handful of architecture decisions early — containerization, versioned data, an extensible data model — that cost very little at discovery scale but save months of re-platforming later. We’ve now run this pattern across programs moving from screening through IND-enabling studies with zero re-platforming events at the transition, simply because the infrastructure was designed to extend rather than be replaced.